Suven Life Sciences Limited Stock Price Today (NSE: SUVEN)

Suven Life Sciences Limited

336.45+3.00 (+0.90%)
Market Closed

Fundamental Score

...

Suven Life Sciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Suven Life Sciences Limited share price today is 336.45, up +0.90% on NSE/BSE as of 16 September 2026. Suven Life Sciences Limited (SUVEN) is a Mid-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of 8.88K (Cr). The 52-week high for SUVEN share price is 403.35 and the 52-week low is 124.11. The company has a Return on Equity (ROE) of -78.80% and a debt-to-equity ratio of 0.00.

Suven Life Sciences Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
403.35
Low
315.00
Volume
9.1L
Change
+7.49%

Suven Life Sciences Limited share price chart: 7.49% return over the past month. 52-week high ₹403.35, 52-week low ₹124.11.

Suven Life Sciences Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
335.00342.00324.00336.455.21L (Cr)
356.35363.95327.10333.458.71L (Cr)
355.00359.95351.50355.553.70L (Cr)
357.75366.70357.75360.702.97L (Cr)
369.90376.75355.05357.507.80L (Cr)
376.45380.00368.00369.904.69L (Cr)
378.70395.40376.10377.158.62L (Cr)
382.00388.45376.70378.004.95L (Cr)
374.00391.00367.75378.3516.93L (Cr)
379.00387.95370.10372.855.56L (Cr)

Suven Life Sciences Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
394.00403.35324.00336.45-14.61%
307.25395.00300.00392.05+27.60%
280.65371.00272.20307.10+9.42%
297.95297.95230.60280.65-5.81%
211.84294.88200.00279.34+31.86%
139.50229.69135.50211.88+51.89%
140.00148.00124.11131.70-5.93%
139.90176.02131.63146.07+4.41%
166.50178.50125.45132.81-20.23%
172.50183.80160.20166.27-3.61%
198.37207.01166.55172.14-13.22%
204.21216.79186.00197.55-3.26%

Returns & Performance

Poor

Return on Equity (ROE)

-78.80%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-78.35%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-1830.23%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Suven Life Sciences Limited Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

39.78x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

67.36%

% shares held by company founders/management

Poor

FII Holding

0.91%

% shares held by foreign institutional investors

Poor

DII Holding

4.62%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-3.78%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

91.02%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-12.00%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-1750.23x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-847.05 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Suven Life Sciences Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SUVEN across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Revenue Growth (91.02%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Healthy Liquidity Position (Current Ratio: 3.21)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (67.36%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

9 factors identified

Below-Average Return on Equity (-78.80%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-78.35%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-1830.23%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

High Price-to-Book Ratio (66.71x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Limited Growth History (-12.00% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Interest Coverage (-1750.23x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-847.05 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 5.53%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Suven Life Sciences Limited vs Healthcare Research, Analytics & Technology Peers

Peer Comparison - Healthcare Research, Analytics & Technology

Compare Suven Life Sciences Limited with 8 other companies in the same sector

9 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
11.4/100
336
₹8882.04
-78.80%
Poor
-78.35%
Poor
0.0
Excellent
-12.00%
Poor
0.00%
35.4/100
387
₹15615.12
70.3
Average
0.00%
Poor
8.43%
Poor
0.0
Excellent
-0.98%
Poor
11.35%
Good
0.30%
57/100
586
₹14101.72
35.1
Average
13.94%
Average
17.29%
Good
0.0
Excellent
23.02%
Excellent
29.44%
Excellent
0.39%
63.6/100
628
₹2805.95
35.2
Average
18.55%
Good
23.39%
Excellent
0.0
Excellent
29.35%
Excellent
14.09%
Good
0.35%
31.2/100
16
₹236.55
18.6
Average
42.11%
Excellent
18.49%
Good
0.0
Excellent
15.08%
Excellent
-41.25%
Poor
0.00%
56.9/100
78
₹164.67
45.3
Average
8.00%
Poor
9.96%
Poor
0.1
Excellent
22.72%
Excellent
151.69%
Excellent
0.00%
28.9/100
92
₹147.94
26.8
Average
1.66%
Poor
5.56%
Poor
3.1
Poor
16.32%
Excellent
3.33%
Average
0.00%
24.6/100
16
₹23.52
19.5
Average
3.38%
Poor
6.02%
Poor
0.2
Excellent
-6.68%
Poor
-3.19%
Poor
0.00%
23.9/100
20
₹13.94
163.6
Average
0.76%
Poor
1.39%
Poor
1.8
Average
-24.21%
Poor
-28.62%
Poor
0.00%

Suven Life Sciences Limited Quarterly Performance

Latest quarterly metrics for SUVEN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

91.02%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-3.78%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-12.00%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Suven Life Sciences Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SUVEN — calculated from daily price history

42RSI 14
Neutral — RSI 42

Momentum is balanced — neither overbought nor oversold.

SMA 50
335
▲ Price above SMA 50 — Short-term bullish
SMA 200
222
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
856K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Suven Life Sciences Limited Financial Statements

Annual income statement, balance sheet and cash flow for Suven Life Sciences Limited (SUVEN) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Suven Life Sciences Limited

Loading latest quarterly results...

About SUVEN (Suven Life Sciences Limited)

Suven Life Sciences Ltd is a pioneering force in the healthcare sector, operating at the intersection of cutting-edge research, advanced analytics, and transformative technology. T...he company dedicates its efforts to unraveling the complexities of neurodegenerative diseases, particularly those affecting the central nervous system. Through rigorous scientific investigation and innovative drug discovery processes, Suven aims to identify and develop novel therapeutic interventions with the potential to significantly improve the lives of patients suffering from conditions like Alzheimer's disease and other neuropsychiatric disorders. Their commitment extends beyond the laboratory, as they actively engage in clinical trials and seek to translate scientific breakthroughs into tangible treatments accessible to patients worldwide. Suven’s approach leverages a blend of sophisticated analytical tools and a deep understanding of disease mechanisms. They meticulously analyze vast datasets to identify potential drug targets and optimize the development of new chemical entities. This data-driven approach, combined with a strong emphasis on intellectual property and strategic partnerships, allows Suven to navigate the challenging landscape of pharmaceutical development with agility and precision. Their research focuses on identifying innovative solutions that address unmet medical needs, striving to provide effective treatments that can slow down disease progression, alleviate symptoms, and ultimately enhance the quality of life for individuals and families affected by debilitating neurological conditions. Driven by a vision of a healthier future, Suven Life Sciences is committed to fostering a culture of scientific excellence and innovation. Their multifaceted operations encompass drug discovery, clinical development, and strategic commercialization planning, all while maintaining a focus on ethical research practices and patient-centered care. By embracing emerging technologies and continually refining their analytical capabilities, Suven positions itself as a dynamic player in the global healthcare arena, working tirelessly to advance the frontiers of neurological disease treatment and contribute to a more hopeful outlook for those affected by these challenging conditions.

Company Details

Symbol:SUVEN
Industry:Healthcare Research, Analytics & Technology
Sector:Healthcare Research, Analytics & Technology

Key Leadership

Mr. Venkateswarlu Jasti M.Pharm. M.S.
CEO, MD & Executive Chairman
Dr. N. V. S. Ramakrishna M.Sc, Ph.D.
President & Chief Scientific Officer
Ms. Sudharani Jasti B.Sc.
Whole-Time Director

SUVEN Share Price: Frequently Asked Questions

What is the current share price of Suven Life Sciences Limited?

Suven Life Sciences Limited (SUVEN) trades at ₹336.45 on NSE and BSE. Market cap ₹8.88K (Cr). Educational data only.

What is the P/E ratio of Suven Life Sciences Limited?

Suven Life Sciences Limited has a P/E of N/Ax vs industry average 39.78x.

What is the Bull Run score for Suven Life Sciences Limited?

Suven Life Sciences Limited has a Bull Run score of 11.4/100 based on 25+ financial parameters.

Does Suven Life Sciences Limited pay dividends?

Suven Life Sciences Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Suven Life Sciences Limited?

Suven Life Sciences Limited has ROE of -78.80%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Suven Life Sciences Limited?

Suven Life Sciences Limited has debt-to-equity of 0.00.

Is Suven Life Sciences Limited a good investment?

Bull Run gives Suven Life Sciences Limited a score of 11.4/100. This is not investment advice — consult a SEBI-registered advisor.